JESSICA CAINE: Open Payments
NPI 1932523552 · MAQUOKETA, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$677 in 36 payments from 10 companies in 2025. Trend: 2023 $917 · 2024 $977 · 2025 $677
Food & beverage: $677
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $148 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| Lundbeck LLC | 3 | $83 |
| ABBVIE INC. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
Products named: CAPLYTA, REXULTI, Auvelity, Qelbree, VRAYLAR, SPRAVATO, COBENFY, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
